CAR NK-cell therapy (allogeneic iPSC-derived, leukemia) (Alphageneron Pharmaceuticals)

N/A

Report date: 2025/01/26 19:05:31

Base Information

Drug NameCAR NK-cell therapy (allogeneic iPSC-derived, leukemia) (Alphageneron Pharmaceuticals)

Drug Alias NameiPSC-derived CAR NK-cell therapy (Alphageneron Pharmaceuticals Inc)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionImmunostimulantsNatural killer cells stimulants

TargetsUpdating

Therapy Area/IndicationsLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAlphageneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesAlphageneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A